TICKERNERD
Menu
MDTMDTHealthcare · Medical Devices

MDT Stock Forecast: Medtronic PLC Price Predictions for 2026-2027

Last close, 14 Aug 2026
$91
+0.76% on the day

The 29 Wall Street analysts covering Medtronic PLC hold a median 12-month price target of $100 — +9.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 83 of 100 as at 13 Aug 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$115.9B
Ticker Nerd rank
83 / 100
Median analyst target
$100
Analysts covering
29
Total return, dividends reinvested
1W
+4.7%
1M
+15.1%
YTD
−3.4%
1Y
+2.4%
From 52W high
−11.2%
From 52W low
+24.9%
$73
$103
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

MDT stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Medtronic PLC on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 13 Aug 2026
83 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
99
Value
93
Issuance
86
Revisions
73
Quality
72
Growth
63
Accruals
57
Momentum
50
Size
2

Volatility (99): The share price has been relatively steady.

Momentum (50): The shares have been drifting down relative to others.

Size (2): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

MDT stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on MDT, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$70$80$90$100$110$120Oct 25Jan 26Apr 26Jul 26MDTHigh $121Median $100Low $78

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says29 analysts
19 Buy10 Hold0 Sell
Low $78Median $100High $121

The green dot is the last close — the median target sits +9.6% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 1 moved their price target up and 2 moved it down.

DateFirmActionRatingTarget
28 July 2026UBSUpgradeBuy$85 → $100
10 July 2026TD CowenMaintainsBuy—
10 July 2026TD CowenMaintainsBuy$119 → $100
6 July 2026Evercore ISI GroupMaintainsOutperform—
6 July 2026Evercore ISI GroupMaintainsOutperform$106 → $105
17 June 2026NeedhamReiteratesBuy—
5 June 2026BernsteinMaintainsOutperform—
5 June 2026Goldman SachsMaintainsNeutral—
4 June 2026BairdMaintainsNeutral—
4 June 2026BTIGUpgradeBuy—
4 June 2026Leerink PartnersMaintainsOutperform—
4 June 2026RBC CapitalReiteratesOutperform—
4 June 2026TD CowenReiteratesBuy—
4 June 2026UBSMaintainsNeutral—
4 June 2026Wells FargoMaintainsOverweight—
3 June 2026MizuhoMaintainsOutperform—
3 June 2026NeedhamMaintainsBuy—
22 Apr 2026UBSMaintainsNeutral—
15 Apr 2026Truist SecuritiesMaintainsHold—
13 Apr 2026MizuhoMaintainsOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. MDT appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

MDT analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
26
Fundamentals

Medtronic PLC (MDT) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
24.3×

Cheaper than 33% of US stocks

Price / sales
3.2×

Cheaper than 40% of US stocks

Price / book
2.3×

Cheaper than 42% of US stocks

EV / EBITDA
13.5×

Cheaper than 28% of US stocks

Growth & margins
Revenue growth (YoY)
9.9%

Higher than 52% of US stocks

Earnings growth (YoY)
17.8%

Higher than 57% of US stocks

Gross margin
65.4%

Higher than 79% of US stocks

Operating margin
22.0%

Higher than 81% of US stocks

Net margin
13.2%

Higher than 75% of US stocks

Returns & dividend
Return on equity
9.8%

Higher than 63% of US stocks

Return on assets
4.9%

Higher than 76% of US stocks

Dividend yield
3.2%

Higher than 68% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

MDT vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
MDTMedtronic PLC$115.9B
83
SYKStryker Corp.$130.4B
74
BSXBoston Scientific Corp.$76.6B
57
ABTAbbott Laboratories$193.5B
53
EWEdwards Lifesciences Corp.$53.3B
91
DXCMDexCom, Inc.$35.3B
98
GEHCGE Healthcare Technologies, Inc.$33.6B
64

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Medtronic PLC — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest MDT news & analysis

Wall Street Bulls Look Optimistic About Medtronic (MDT): Should You Buy?

Zacks Investment Research · 13 Aug 2026positive

A Zacks Investment Research article notes that Wall Street (sell-side) analysts hold an optimistic view on Medtronic. It discusses how analyst ratings and rating changes, which are commonly used by investors, can influence the company's stock price.

Why it matters — Medtronic watchers would care because analyst sentiment and rating changes are signals that can affect the company's share price and investor perceptions.

Medtronic (MDT) Increases Despite Market Slip: Here's What You Need to Know

Zacks Investment Research · 10 Aug 2026positive

Medtronic (MDT) shares closed at $89.41 on the recent trading day, a +2.58% increase from the prior session, even as the broader market slipped. The move was highlighted by Zacks Investment Research.

Why it matters — A Medtronic watcher would note that the stock advanced against a declining market, signaling relative strength in the company's latest trading performance.

Medtronic: Buy This Undervalued Dividend Aristocrat Before The Market Catches On

Seeking Alpha · 10 Aug 2026positive

Seeking Alpha rated Medtronic a 'Buy', citing strong growth in cardiac ablation (124% U.S. segment growth) and rapid expansion of the Hugo robotic surgery platform. Management guided for 11.75% organic revenue growth in Q1 2027, with CAS expected to outpace the market.

Why it matters — MDT watchers would note the strong growth metrics in key segments like cardiac ablation and Hugo robotics, as well as management's bullish organic revenue guidance for Q1 2027.

We Said These 4 Dividend Aristocrats Could Soar. Here's How They Did, Plus 3 New Picks.

24/7 Wall Street · 10 Aug 2026neutral

About a year after 24/7 Wall Street flagged four overlooked Dividend Aristocrats as stealth growth plays, the outlet reviewed how those picks performed and introduced three new selections. The update evaluates whether the overlooked income names delivered upside when the market took notice.

Why it matters — For a Medtronic watcher, the article's focus on overlooked Dividend Aristocrats as potential growth plays is relevant because MDT belongs to the same category of companies the piece evaluates and selects from.

Medtronic vs. Intuitive Surgical: Which MedTech Stock Is the Better Buy Right Now?

The Motley Fool · 8 Aug 2026positive

The Motley Fool compares Medtronic and Intuitive Surgical as potential investments. Medtronic has launched new devices expected to further improve its financial results, while Intuitive Surgical's latest da Vinci system could expand its addressable market.

Why it matters — The article highlights Medtronic's recent product launches as a positive development that could support its financial performance.

FAQ

Frequently asked questions about MDT stock

What is the MDT stock price forecast for 2026-2027?

The 29 Wall Street analysts covering Medtronic PLC have a median 12-month price target of $100, with estimates ranging from $78 to $121. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is MDT stock a buy right now?

Of the 29 analysts covering Medtronic PLC, 19 rate it a Buy, 10 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Medtronic PLC 83 out of 100 across roughly 4,600 US stocks as at 13 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank MDT?

As at 13 Aug 2026, Medtronic PLC ranks 83 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (99 of 100).

Will MDT stock go up?

No one can know that. What the data says: the median 12-month target from 29 analysts implies +9.6% from the last close, and Ticker Nerd's factor model ranks Medtronic PLC 83 out of 100 as at 13 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the MDT stock forecast for 2030?

No analyst covering Medtronic PLC publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MDT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $78 to $121 over the next 12 months.

How has MDT stock performed over the past year?

Medtronic PLC returned +2.4% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Medtronic PLC do?

Medtronic plc is a global medical technology company that develops, manufactures, and sells device-based therapies and related services for a broad range of chronic and acute health conditions. Headquartered in Dublin, Ireland, and founded in 1949, Medtronic focuses on technologies used by hospitals, clinics, and physicians worldwide.

What is the latest news on MDT?

The most recent item we track (Zacks Investment Research, 13 Aug 2026): "Wall Street Bulls Look Optimistic About Medtronic (MDT): Should You Buy?". A Zacks Investment Research article notes that Wall Street (sell-side) analysts hold an optimistic view on Medtronic. It discusses how analyst ratings and rating changes, which are commonly used by investors, can influence the company's stock price.

Company

About Medtronic PLC.

Medtronic plc is a global medical technology company that develops, manufactures, and sells device-based therapies and related services for a broad range of chronic and acute health conditions. Headquartered in Dublin, Ireland, and founded in 1949, Medtronic focuses on technologies used by hospitals, clinics, and physicians worldwide. The company operates through four main areas: its Cardiovascular Portfolio, offering products such as heart valves, stents, pacemakers, and defibrillators; its Neuroscience Portfolio, which provides spinal fixation systems, neurostimulation devices, and neurovascular products; its Medical Surgical Portfolio, supplying advanced surgical instruments, energy-based devices, and visualization tools; and its Diabetes Operating Unit, which delivers insulin pumps, continuous glucose monitoring systems, and related consumables. Medtronic plays a significant role in the healthcare sector by providing solutions that support the diagnosis, monitoring, and treatment of complex conditions, serving healthcare providers and patients across the United States, Europe, Japan, and other international markets.

CEO Mr. Geoffrey Straub Martha · 95,000 employees · Ireland · https://www.medtronic.com